Overview

Exparel Use in Adductor Canal Block After Total Knee Arthroplasty

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
Exparel has been shown to have better pain control compared to previously used infiltration agents, including bupivacaine, while having a minor side effect profile. The purpose of this study is to explore the effectiveness of Exparel (liposomal bupivacaine) in Adductor Canal Blocks for peri-operative pain control following a total knee arthroplasty (TKA) procedure.
Phase:
Phase 3
Details
Lead Sponsor:
St. Luke's Hospital, Pennsylvania
Treatments:
Ropivacaine